Aquestive’s Anaphylm could become the first oral epinephrine for severe allergic reactions after the FDA set a 2026 decision date without panel review.
Latest Ratings for AQST
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 2020 | RBC Capital | Maintains | Outperform | |
| Sep 2020 | HC Wainwright & Co. | Maintains | Buy | |
| May 2020 | HC Wainwright & Co. | Maintains | Buy |
